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Context
Malaria in pregnancy has devastating consequences for mother and
fetus. WHO recommends intermittent preventive treatment in pregnancy
(IPTp) with treatment doses of an efﬁcacious antimalarial during the
second and third trimesters of pregnancy at predeﬁned intervals.
Sulfadoxine–pyrimethamine is currently recommended, but high-level
parasite resistance threatens its efﬁcacy. Recent trials showed that amo-
diaquine, meﬂoquine and chloroquine–azithromycin are not suitable
alternatives due to poor tolerability. This trial by Kakuru et al evaluated
the artemisinin-based combination therapy (ACT), dihydroartemisinin–
piperaquine, for IPTp. Dihydroartemisinin–piperaquine is already recom-
mended by WHO for treatment of malaria in the second and third trime-
sters. A recent comparison of four ACTs for treatment of malaria in
pregnancy in Africa showed that dihydroartemisinin–piperaquine had the
best efﬁcacy and a long post-treatment prophylactic effect, which sup-
ports its suitability for IPTp in high transmission areas.1
Methods
The trial by Kakuru et al was a double-blind, randomised, controlled,
three-arm trial comparing three-course dihydroartemisinin–piperaquine
and monthly dihydroartemisinin–piperaquine versus the standard three-
course sulfadoxine–pyrimethamine regimen as IPTp among HIV-
uninfected pregnant women between 12 and 20 weeks gestation, using a
1:1:1 allocation. The study was conducted in an area of high sulfadoxine–
pyrimethamine resistance in Uganda. The primary outcome was the preva-
lence of histopathology-conﬁrmed placental malaria. Secondary outcomes
included symptomatic malaria, parasitaemia, anaemia and adverse birth out-
comes. Women and newborns were followed up to 6 weeks post delivery.
Findings
Three hundred women were enrolled. The dihydroartemisinin–piperaquine
regimens were well tolerated. Compared with sulfadoxine–pyrimeth-
amine, three-course and monthly dihydroartemisinin–piperaquine regi-
mens were associated with a 67% and 100% reduction in incidence of
clinical malaria during pregnancy, respectively; a 32% and 46% reduc-
tion in malaria infection at delivery; and a 13% and 34% lower risk of
anaemia at delivery. Compared with sulfadoxine-pyrimethamine, the
relative risk of a composite adverse birth outcome was 0.49 (95% CI 0.23
to 1.04) in the monthly dihydroartemisinin–piperaquine arm, and slightly
higher (RR 1.15 95% CI 0.65 to 2.02) in the three-course arm, compared
with sulfadoxine–pyrimethamine. There were no differences in safety or
adverse events by study arm.
Commentary
This exploratory trial showed that IPTp with dihydroartemisinin–pipera-
quine was superior to sulfadoxine–pyrimethamine in reducing malaria
infections during pregnancy in an area of high sulfadoxine–pyrimeth-
amine resistance, however the study was not powered to detect differences
in adverse birth outcomes. The results are consistent with another trial in
western Kenya, which showed that, relative to IPTp with sulfadoxine–pyri-
methamine, three-to-four courses of dihydroartemisinin–piperaquine
resulted in similarly high reductions in clinical malaria and malaria infec-
tion, and was also associated with up to a 75% lower risk of stillbirths and
early infant mortality.2 Interestingly, the Uganda trial also showed that
monthly dosing results in added beneﬁts over three-course dihydroartemisi-
nin–piperaquine or sulfadoxine–pyrimethamine regimens, consistent with a
meta-analysis of monthly versus two-course sulfadoxine–pyrimethamine.3
Implications for practice
The WHO’s Malaria Policy Advisory Committee reviewed the results from
both Ugandan and Kenyan trials, and concluded that dihydroartemisi-
nin–piperaquine is a promising regimen for IPTp, and recommended that
larger trials be conducted, powered to look at efﬁcacy on adverse preg-
nancy outcomes and to provide further reassurance on safety.4
Furthermore, questions remain regarding pregnant women’s adherence
to dihydroartemisinin–piperaquine, a 3-day regimen, in non-controlled
settings.5 Similarly, feasibility studies on the ability of antenatal care
service providers to deliver the intervention in routine healthcare settings
are also needed, given that coverage with the existing single-dose policy
with sulfadoxine–pyrimethamine is already suboptimal.6 It is estimated
these studies may take 3–4 years. If these promising ﬁndings are con-
ﬁrmed, it is likely to result in policy change in countries experiencing high
levels of parasite resistance, including most countries in East and Southern
Africa, beneﬁting women at risk of malaria in these regions, and resulting
in healthier pregnancies and healthier newborns.
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